Abstract:Aim: The objective of this trial is to explore the efficacy and safety of erlotinib (Tarceva ®) as neoadjuvant treatment in stage IIIA-N2 NSCLC patients with activating EGFR mutation. Methods: Previously untreated patients with endobronchial ultrasound confirmed stage IIIA-N2 NSCLC with activating EGFR mutation in exon 19 or 21 were recruited into the study. All enrolled patients were treated with erlotinib 150mg orally per day for 56 days for neoadjuvant period. Only patients who got benefits from erlotinib treatment and were resectable would receive surgery. The primary endpoint is radical resection rate. The secondary endpoints included pathological complete response rate, objective response rate, disease free survival, overall survival, safety profile, and explorative biomarkers. This study was registered in clinicaltrials.gov (NCT01217619). Results: From 10 Oct 2010 to 30 Jun 2014, total 155 patients were screened, 44 patients with IIIA N2, 25 patients (with IIIA N2 EGFR Mutations) were finally enrolled into the study (Table 1). After erlotinib treatment, RR32%, DCR76%. Sixteen patients underwent resection surgery. Fifteen patients (93.8%) had R0 resection and the radical resection rate was 60% (15/25). pCR6.3%; pRR93.7%. The median DFS were 10.4 months. OS data are not mature. All patients were consistent on EGFR mutation before and after the surgery except three patients with exon 19 deletion turn to EGFR wild type after the surgery. Seven patients (28%,7/25) had rash(grade I-II) and one patient had diarrhea(grade I) after erlotinib treatment. Table 1.Tabled 1Patient and disease characteristicsItemsTotal enrolled (n = 25)No surgery (n = 9)Surgery (n = 16)Age, median (range), year59 (33,74)59 (33,74)60 (38,73)Sex,male/female13/127/26/10ECOG, n (%)125 (100%)9 (100%)16 (100%)Current or former smoker/never-smoker12/137/25/11EGFR mutation type before erlotinib, n(%)exon 19 deletion16 (64%)6 (66.7%)10 (62.5%)exon 21 L858R mutation10 (40%)4 (44.4%)*one patient had both exon 19 deletion and exon 21 L858R point mutation.6 (37.5%)Carcinoembryonic antigen, µg/L, mean (S.D.)Before treatment78.2 (140.6)120.8 (185.9)54.2 (99.2)4 weeks after erlotinib41.7 (86.7)89.7 (124.0)12.2 (19.9)7 weeks after erlotinib33.2 (61.9)106.8 (92.4)10.6 (14.5)after surgeryNANA3.2 (2.2)AE during erlotinib treatment, n(%)Rash7 (28%)2 (22.2%)5, (31.3%)Diarrhea1 (4%)01 (6.3%)Abnormal liver function1 (4%)1 (11.1%)0Leukocytopenia1 (4%)1 (11.1%)0Cerebral infarction1 (4%)1 (11.1%)0Reason for no surgeryProgress of disease6NASerious AE (cerebral infarction)1NANot suitable for surgery2NA* one patient had both exon 19 deletion and exon 21 L858R point mutation. Open table in a new tab Conclusions: Erlotinibas neoadjuvant therapyis a promising treatment for EGFR mutant IIIA-N2 NSCLC patients with tolerable toxicity. Clinical trial identification: (NCT01217619, ESTERN) 10-2010 Disclosure: All authors have declared no conflicts of interest.

EP07.05-02 NEOEAST: A Phase II Study of Ensartinib As Neoadjuvant Therapy for Stage II-IIIB ALK-rearranged Non-small Cell Lung Cancer

P2.03a-001 A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

P2.01-02 Neoadjuvant Targeted Therapy for Resectable ALK-fusion Locally Advanced Non-small Cell Lung Cancer

Erlotinib As Neoadjuvant Treatment in Patients with Iiia-N2 Non-Small Cell Lung Cancer(Nsclc) with Activating Epidermal Growth Factor Receptor (egfr) Mutation (nct01217619, Estern)

Camrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Oesophageal Squamous Cell Carcinoma: a Single-Arm Phase 2 Trial

EP05.02-016 Aumolertinib after Adjuvant Chemotherapy/Radiotherapy in Stage Piiia-N2 Non-Small-Cell Lung Cancer with EGFR Mutation

A phase 1b study of ensartinib in combination with platinum-based chemotherapy and bevacizumab in ALK-positive non-small cell lung cancer (NSCLC).

Neoadjuvant target therapy with ensartinib in lung adenocarcinoma with EML4-ALK fusion variant: a case report and literature review

EP08.02-136 Final Analysis of a Phase II Study: Anlotinib Plus Docetaxel in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer

Erlotinib As Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study

OA 16.04 Efficacy and Safety of Erlotinib Vs Vinorelbine/Cisplatin As Adjuvant Therapy for Stage IIIA EGFR Mutant NSCLC Patients

Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial

Erlotinib As Neoadjuvant Treatment in Endobronchial Ultrasound Confirmed Stage IIIA-N2 Non-Small Cell Lung Cancer (NSCLC) Patients with Epidermal Growth Factor Receptor (EGFR) Mutation (EXON 19 OR 21) (NCT01217619, ESTERN): a Prospective, Single Arm, Phase Ii Clinical Trial

Erlotinib Versus Gemcitabine Plus Cisplatin As Neoadjuvant Treatment Of Stage Iiia-N2 Egfr-Mutant Non-Small-Cell Lung Cancer (Emerging-Ctong 1103): A Randomized Phase Ii Study

Effect Of Intercalated Erlotinib With Gemcitabine/Cisplatin As Neoadjuvant Treatment In Stage Iiia Unrectable Non-Small Cell Lung Cancer (Ctong 1101, Nct01297101) On Disease-Free Survival: A Single Arm, Multi-Center, Phase Ii Study.

Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study

Gefitinib as neoadinvant therapy for resectahle stage II-IIIA non-small cell lung cancer: A phase II study

eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients.

Neoadjuvant Alectinib in Locally Advanced Lung Adenocarcinoma with Anaplastic Lymphoma Kinase Rearrangement: Case Series and Literature Review

Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports

A phase II study of epirubicin combined with anlotinib followed by anlotinib in the first-line treatment of advanced unresectablesoft tissue sarcoma.